THE DEAL, AT A GLANCE
From the announcementVaxdyn
01What it doesVaxdyn is building vaccines using a proprietary technology platform to target bacteria the World Health Organization considers critical threats to human health.From the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗02What happenedVaxdyn raised $13M Series A, announced 2026-09-07From the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗03Why it mattersVaxdyn’s $13M Series A is a below-median FinTech-classified round attached to a vaccines company focused on drug-resistant bacteria, creating a capital-flow signal that…From the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗Click a part to explore its evidence. Unsupported imagery is withheld rather than guessed.Original record source ↗
Vaxdyn · Financing Record
Explore source-linked visual explanations for Vaxdyn. Unsupported claims are withheld while source review continues.
Record 11801 · Recorded date: 2026-09-07
Explore company records →